Four SFXN2 CpG sites (Figure 3b) were found, of which two CpG sites (3′-UTR-Open_Sea-cg04774043 and Body-Open_Sea-cg18994254) were significantly associated with the prognosis of BC patients (Table 3). This evidence concerns the gene SFXN2 and breast cancer.